Elicio Therapeutics Inc
NASDAQ:ELTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Elicio Therapeutics Inc
Cash from Financing Activities
Elicio Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elicio Therapeutics Inc
NASDAQ:ELTX
|
Cash from Financing Activities
$36.7m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$5.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
-11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$1.9B
|
CAGR 3-Years
40%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Elicio Therapeutics Inc
Glance View
Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. The company is headquartered in Boston, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. The company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The firm's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). The company is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The firm is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The firm provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The firm conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
See Also
What is Elicio Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
42.3m
USD
Based on the financial report for Dec 31, 2024, Elicio Therapeutics Inc's Cash from Financing Activities amounts to 42.3m USD.
What is Elicio Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
54%
Over the last year, the Cash from Financing Activities growth was 10%. The average annual Cash from Financing Activities growth rates for Elicio Therapeutics Inc have been -27% over the past three years , 54% over the past five years .
